Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

l trial for elagolix, the  most advanced clinical program in the Company's pipeline, will fail to support the additional Phase III clinical trial required for regulatory approval; risk that the elagolix Phase III program overall will encounter delays for regulatory or other reasons; risk that the elagolix Phase III clinical program will fail to demonstrate that elagolix is safe and effective for the treatment of endometriosis or support filings for regulatory approval; risk that the uterine fibroid elagolix clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of uterine fibroids; and  risks associated with the Company's dependence on corporate collaborators for Phase III development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the rest of the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's repor
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... senior lecturer in mechanical engineering at the University of ... Year by the North Texas section of the American ... than 130,000 members in 158 countries who develop engineering ... the engineering community, benefiting the world. , ASME recognized ... Professional Engineers honors banquet. Baughn retired as an engineering ...
(Date:7/22/2014)... 2014 Rice Lake Weighing ... 2014 NCSL International Workshop and Symposium July 28-31 ... CONDEC pressure instrumentation, OIML M1 weights, precision lab ... customized sets, Essential Weights™. , NCSL International was ... in solving the common problems faced by measurement ...
(Date:7/22/2014)... og SHENZHEN , Kina, 22. ... LTD, (BGI Tech), et datterselskab af BGI, verdens ... ny human whole exome-sekvenseringstjeneste baseret på Complete Genomics ... anset i branchen for at levere patenterede sekvenseringsteknologier ... alle typer varianter, blev købt af BGI i ...
(Date:7/22/2014)... Switzerland (PRWEB) July 22, 2014 ... are becoming an increasingly common sight. The rapid ... they are now well- established as a core ... low maintenance has made them the gas analyzer ... locations and conditions encountered in some processes have ...
Breaking Biology Technology:UT Dallas professor receives Engineer of the Year award 2Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2
... 2011 Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical ... today announced its third quarter financial results for 2011. ... Nile reported research and development collaboration income relating to ... to none in the third quarter of 2010. The ...
... 13, 2011 Pharmasset, Inc. (Nasdaq: VRUS ) ... 8th Annual Healthcare Conference to be held November 15 to ... Pharmasset,s President and Chief Executive Officer, will provide an overview ... (ET). To access a simultaneous webcast of Mr. ...
... 2011 Spherix Incorporated (NASDAQ: SPEX ) ... metabolic syndrome and atherosclerosis, and providers of technical and ... companies -- today reported financial results for the three ... Recent and Upcoming Highlights ...
Cached Biology Technology:Nile Therapeutics Reports 2011 Third Quarter Financial Results 2Nile Therapeutics Reports 2011 Third Quarter Financial Results 3Nile Therapeutics Reports 2011 Third Quarter Financial Results 4Nile Therapeutics Reports 2011 Third Quarter Financial Results 5Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 3Spherix Announces Third Quarter Financial Results 2Spherix Announces Third Quarter Financial Results 3Spherix Announces Third Quarter Financial Results 4Spherix Announces Third Quarter Financial Results 5Spherix Announces Third Quarter Financial Results 6Spherix Announces Third Quarter Financial Results 7
(Date:7/22/2014)... 2014) New research from the Monell Center reveals ... can increase airway inflammation in asthmatics for at least ... that expectations can play in health-related outcomes. , "Asthmatics ... expect that an odor is harmful, our bodies react ... lead author Cristina Jan, PhD, a Monell physiologist. "Both ...
(Date:7/22/2014)... be good for the average steak, but it seems ... to survive Alaska,s winter cold. , "Alaska wood frogs ... steak does in your freezer and the frog comes ... than the steak," said Don Larson, University of Alaska ... paper demonstrating that freeze tolerance in Alaska wood frogs ...
(Date:7/22/2014)... to dust mites (and chances are you are), help ... University of Iowa have developed a vaccine that can ... response. In animal tests, the nano-sized vaccine package lowered ... the allergens, according to the paper, published in the ... Journal . One big reason why it works, the ...
Breaking Biology News(10 mins):In asthma, it's not just what you smell, but what you think you smell 2In asthma, it's not just what you smell, but what you think you smell 3Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3Researchers create vaccine for dust-mite allergies 2
... (Boston) A new study from Boston University School ... pluripotent stem (iPS) cells in an experimental model were ... The study, published online in Cell Stem Cell ... develop cell types that could offer treatment for a ...
... new study that provides surprising details on changes in Earth,s ... last interglacial--the period between "ice ages"--was warmer than previously thought ... greenhouse gases increase in the atmosphere and global temperatures rise. ... the massive West Antarctic ice sheet may have contributed more ...
... led by Associate Professor Kenji Osafune and his colleague ... and Application (CiRA), Kyoto University in Japan, has succeeded ... induced pluripotent stem (iPS) cells to differentiate into intermediate ... lineages. This represents a major step toward realizing renal ...
Cached Biology News:BUSM study shows potential of differentiated iPS cells in cell therapy without immune rejection 2Analysis of Greenland ice cores adds to historical record and provide glimpse into climate's future 2Analysis of Greenland ice cores adds to historical record and provide glimpse into climate's future 3Analysis of Greenland ice cores adds to historical record and provide glimpse into climate's future 4Monitoring and robust induction of nephrogenic intermediate mesoderm from human iPSCs 2
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
... an evolutionarily conserved form of cell suicide, ... The central component of this process is ... These enzymes participate in a series ... to pro-apoptotic signals and result in the ...
... DNA Visualizer Extraction Kit is manufactured for ... DNA damage byexposure to UV light. The ... is often used for DNA-cloning work. The ... bromide and exposure of UV light damages ...
...
Biology Products: